This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Age 18 years or older, of either sex;
Acute ischemic stroke caused by occlusion of the basilar artery;
Decide to undergo emergency endovascular treatment;
Time from stroke onset to groin puncture within 24 hours;
Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;
Pre-stroke modified Rankin scale (mRS) score >1;
Known allergy to tocilizumab or excipients;
Known allergy to iodinated contrast agents;